BibTex format
@article{Girón-Callejas:2025:10.1186/s12981-025-00788-8,
author = {Girón-Callejas, A and Lorenzana, R and Pickles, M and Inzaule, S and Jordan, MR and Diaz, S and Vrinten, C},
doi = {10.1186/s12981-025-00788-8},
journal = {AIDS Research and Therapy},
title = {High HIV viral suppression among adults receiving WHO-recommended first-line dolutegravir-based antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis of programmatic evidence},
url = {http://dx.doi.org/10.1186/s12981-025-00788-8},
volume = {22},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BackgroundThis systematic review and meta-analysis assessed viral suppression among adults receiving WHO-recommended first-line dolutegravir-based ART in programmatic settings in low- and middle-income countries (LMICs).MethodsA systematic search of Ovid MEDLINE, Embase, and major HIV conferences (IAS, AIDS, and CROI) from January 2019 to September 2024 identified cohort and cross-sectional studies reporting viral suppression among adults receiving WHO-recommended first-line dolutegravir-based ART in LMICs. Studies with follow-ups ≤ 4 months or using non-WHO-recommended regimens were excluded. Pooled estimates were calculated using random-effects meta-analysis. Sensitivity analyses excluded outliers. Subgroup analyses distinguished adults initiating versus transitioning to dolutegravir-based ART. Both on-treatment and intention-to-treat outcomes were assessed.ResultsTwenty-two studies (n = 47 to 50,742) from 13 countries were included. On-treatment pooled viral suppression was 95% (95% CI: 91–97%, I²= 96%) at six months, 96% (94–98%, I² = 97%) at 12 months, and 98% (96–99%, I² = 94%) at 24 months. Sensitivity analysis removing outliers decreased heterogeneity and slightly lowered the 6month estimate (to 94%), with negligible change at 12 months. At 6 months, viral suppression was higher in those transitioning than initiating ART (98% vs. 94%, p < 0.01), with similar rates at 12 months (97%, p = 0.67). The pooled intention-to-treat 12-month viral suppression rate was 89% (82–93%, I² = 95%), with no significant difference by ART status (initiating 86% vs. transitioning 91%, p = 0.44).ConclusionAdults retained in care receiving WHO-recommended first-line dolutegravir-based ART achieved viral suppression rates of ≥ 95% up to two years. These findings align with the UNAIDS 95% suppression target and reinforce the role of dolutegravir-based re
AU - Girón-Callejas,A
AU - Lorenzana,R
AU - Pickles,M
AU - Inzaule,S
AU - Jordan,MR
AU - Diaz,S
AU - Vrinten,C
DO - 10.1186/s12981-025-00788-8
PY - 2025///
SN - 1742-6405
TI - High HIV viral suppression among adults receiving WHO-recommended first-line dolutegravir-based antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis of programmatic evidence
T2 - AIDS Research and Therapy
UR - http://dx.doi.org/10.1186/s12981-025-00788-8
UR - https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-025-00788-8
VL - 22
ER -